|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
MAO INHIBITORS PROLONG & INTENSIFY THE ANTICHOLINERGIC EFFECTS OF ANTIHISTAMINICS
|
SUMATRIPTAN WHEN CONCURRENTLY GIVEN IN A PATIENT HAVE INCREASED CHANCES OF DEVELOPING SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
CONCURRENT AND/OR SEQUENTIAL USE WITH MAO INHIBITORS IS NOT RECOMMENDED DUE TO HYPERTENSIVE CRISIS OR OTHER SERIOUS SIDE EFFECTS
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
INCREASED SEDATIVE EFFECT
|
GATIFLOXACIN MAY HAVE THE POTENTIAL TO PROLONG THE QT INTERVAL ; CO-ADMINISTRATION WITH DRUGS KNOWN TO PROLONG QT INTERVAL SHOULD BE AVOIDED
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
INSULIN REQUIREMENT IS DECREASED BY THE DRUG
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|